The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
Firmonertinib failed to significantly improve progression-free survival over chemotherapy in the BICR analysis, though secondary measures showed some benefit.